Vallera DA - Search Results

1

Peptide toxins directed at the matrix dissolution systems of cancer cells.

Frankel AE, Bugge TH, Liu S, Vallera DA, Leppla SH. Frankel AE, et al. Among authors: vallera da. Protein Pept Lett. 2002 Feb;9(1):1-14. doi: 10.2174/0929866023409048. Protein Pept Lett. 2002. PMID: 12141918 Review.

2

Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.

Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA. Frankel AE, et al. Among authors: vallera da. Exp Hematol. 2002 Nov;30(11):1316-23. doi: 10.1016/s0301-472x(02)00925-6. Exp Hematol. 2002. PMID: 12423685 Free article.

3

The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.

Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. Ramage JG, et al. Among authors: vallera da. Leuk Res. 2003 Jan;27(1):79-84. doi: 10.1016/s0145-2126(02)00077-2. Leuk Res. 2003. PMID: 12479856

4

Chimeric fusion proteins--diphtheria toxin-based.

Frankel AE, Powell BL, Vallera DA, Neville DM Jr. Frankel AE, et al. Among authors: vallera da. Curr Opin Investig Drugs. 2001 Sep;2(9):1294-301. Curr Opin Investig Drugs. 2001. PMID: 11717818 Review.

5

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. Vallera DA, et al. Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530709 Free PMC article.

6

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Bachanova V, et al. Among authors: vallera da. Clin Cancer Res. 2015 Mar 15;21(6):1267-72. doi: 10.1158/1078-0432.CCR-14-2877. Clin Cancer Res. 2015. PMID: 25770294 Free PMC article. Clinical Trial.

7

Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.

Vallera DA, Burns LJ, Frankel AE, Sicheneder AR, Gunther R, Gajl-Peczalska K, Pennell CA, Kersey JH. Vallera DA, et al. J Immunol Methods. 1996 Oct 16;197(1-2):69-83. doi: 10.1016/0022-1759(96)00127-5. J Immunol Methods. 1996. PMID: 8890895

8

Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.

Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Frankel AE, et al. Among authors: vallera da. Leuk Lymphoma. 1997 Jul;26(3-4):287-98. doi: 10.3109/10428199709051778. Leuk Lymphoma. 1997. PMID: 9322891 Clinical Trial.

9

Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.

Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. Li C, et al. Among authors: vallera da. Protein Eng. 2002 May;15(5):419-27. doi: 10.1093/protein/15.5.419. Protein Eng. 2002. PMID: 12034862

10

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA. Oh S, et al. Among authors: vallera da. Pancreas. 2010 Aug;39(6):913-22. doi: 10.1097/MPA.0b013e3181cbd908. Pancreas. 2010. PMID: 20182395 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page